Trial Categories: Acute Coronary Syndromes
Evaluated clopidogrel versus placebo added to aspirin during non-ST elevation MI or unstable angina. There was a significant reduction in the composite endpoint of death from cardiovascular causes, nonfatal MI, and stroke. The CURE trial led to the recommended to use clopidogrel as medical management for non-ST elevation myocardial infarctions and unstable angina.
N Engl J Med. 2001 Aug 16;345(7):494-502.
Eponym: Clopidogrel in Unstable angina to prevent Recurrent Events
Purpose: The evaluate clopidogrel (Plavix) when added to aspirin during unstable angina or non-ST segment elevation myocardial infarction.
Format: Double-blind, multicenter, randomized control trial
Treatment Group: Clopidogrel
Control Group: Placebo
Number of Patients: 12,562
Within 24 hours of symptom onset
No ST segment elevation
New ischemic ECG changes OR elevation in cardiac enzymes
Contraindication to antithrombotic or antiplatelet therapy
High bleeding risk
Severe heart failure
Patients taking oral anticoagulants
Coronary revascularization within the previous 3 months
Patients that had received glycoprotein IIb/IIIa inhibitors within the prior 3 days
Follow-up: Three to twelve months
Primary endpoint: Composite of cardiovascualr death, non-fatal MI and stroke
Need for revascularization
Major bleeding (requiring 2 or more units of blood transfusion)
Review of Unstable Angina and Non-ST elevation MI